SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is seeing intense market interest and speculative trading following the unveiling of 'Thunder,' a jointly-developed autonomous VTOL aircraft platform with Anduril Industries aimed at both defense and commercial markets. While the community is actively debating the significance of this defense pivot and upcoming commercial customer announcements, sentiment remains split between bullish investors focused on long-term partnerships and skeptics concerned about the company's cash burn and technical progress.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently seeing heightened volatility and intense community debate as the stock experiences a significant pullback from recent highs, fueled by broader space sector turbulence and shifts in institutional sentiment. While bears argue the company is overvalued and lacking near-term profitability, many investors remain bullish on the long-term potential of the Neutron launch vehicle and the company's vertically integrated space infrastructure strategy.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery shareholders are preparing for a pivotal vote on the proposed $110 billion merger with Paramount Skydance, with market sentiment heavily focused on the significant cash premium offered in the deal. Investors are closely monitoring potential regulatory hurdles and the contentious debate surrounding the CEO's executive compensation package, as the merger faces ongoing scrutiny from industry figures and lawmakers concerned about media consolidation.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is seeing strong momentum following the announcement of multi-year AI cloud contracts valued at over $2 billion, which significantly bolster its revenue outlook and customer diversification. Investors are actively debating the company's ability to execute on its massive AI infrastructure scale-up versus the dilutive impact of ongoing capital raises.

USA Rare Earth, Inc. is a domestic supplier of rare earth magnets and heavy rare earth elements. It develops a vertically integrated domestic supply chain for rare earth element magnet production, with a facility in Stillwater and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending as the market evaluates its strategic position following new U.S. executive orders that limit reliance on foreign-sourced critical minerals and prioritize domestic supply chain security. While the community is actively debating the company's leadership transition and the impact of recent government funding, sentiment remains divided between those betting on the stock as a long-term play on national security and those expressing frustration over short-term price volatility.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital is gaining momentum as investors focus on its data center infrastructure and behind-the-meter power capacity, with the community closely tracking upcoming potential lease news and the company's recent inclusion in the Russell indexes. Bullish sentiment is being driven by demand for AI power solutions, while active discussions center on the stock's technical setup and anticipation for a major revaluation following potential tenant announcements.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Georgetown, TX.

TSS Inc

TSS Inc. is facing significant selling pressure as investors react to a year-over-year revenue decline, despite the company highlighting an 88% surge in higher-margin systems integration revenue. The community is actively debating whether the stock represents a deep-value buying opportunity driven by AI infrastructure demand or a high-risk gamble due to intense customer concentration with Dell and ongoing insider selling.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is experiencing significant market interest as investors rotate into high-growth consumer brands, fueled by strategic expansions into the haircare market and recent analyst price target upgrades. Community sentiment remains polarized between long-term bulls highlighting strong brand loyalty and fundamentals, and skeptical bears focused on technical price pressure and macroeconomic headwinds.

Phoenix Asia Holdings Ltd. engages in the substructure works and other construction services. It offers site formation, ground investigation and foundation work through it subsidiary. The company was founded on August 9, 2024 and is headquartered in Hong Kong.

Phoenix Asia Holdings Ltd.

Phoenix Asia Holdings is trending due to significant retail speculation following a proposed billion-dollar acquisition of ACEA Pharma, which has sparked intense debate over the company's valuation and the legitimacy of the deal. Community discourse is highly polarized, with active traders attempting to drive a short squeeze through aggressive buying campaigns while skeptics warn of potential manipulation and pump-and-dump mechanics reminiscent of previous speculative small-cap volatility.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors weigh recent institutional moves and executive leadership changes against the upcoming expiration of the TDAPA reimbursement period for DefenCath. The community is actively debating the potential impact of pending kidney care legislation and speculating on future acquisition or merger possibilities while tracking ongoing adoption rates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CMPS $DFTX $HELP 

Strong point.

But doesn&#39;t explain why CMPS is 4x HELP mkt cap (2x might be about right - efficacy aside, relative just to time to outcome) and DFTX is 3.5 almost 4x CMPS mkt cap.

Perhaps then it appears that DFTX is appropriately priced given probable TAM in a multi-player market - and both CMPS and HELP are due to triple.

Or perhaps DFTX is due to double again and the others 6x. 

Lets see.

Cybin

Glen 'Rocky' Meyers

Waldo Smallz

StockTwits for iOS

COMPASS Pathways

Definium Therapeutics Inc.

Helus Pharma Inc.

Millionaire11

StockTwits For Android 

 

Strong point.

But doesn't explain why CMPS is 4x HELP mkt cap (2x might be about right - efficacy aside, relative just to time to outcome) and DFTX is 3.5 almost 4x CMPS mkt cap.

Perhaps then it appears that DFTX is appropriately priced given probable TAM in a multi-player market - and both CMPS and HELP are due to triple.

Or perhaps DFTX is due to double again and the others 6x. 

Lets see.

Jasper

@RuddyRolls No matter the scenario $CMPS is undervalued.

Ron S

@Millionaire11 agreed.

And HELP is super undervalued.

I don&#39;t think there is any shortage (whatsoever) of pie to divide up relative to mature global market demand for these &quot;products&quot; (I hesitate to describe such potential life changing miracle treatments in such banal commercial terms - but this is financial analysis and so that is the lense for investors).

Rather I think we are very early in this space. Still nascent, but about to bloom.

Long hold a position in the lot as an investor - and thereby spread your risk over multiple shots on goal for approval.

Traders can assess for themselves sentiment, momentum and risk/ reward profiles for each - they have The Time/ Attention space to do so.

 agreed.

And HELP is super undervalued.

I don't think there is any shortage (whatsoever) of pie to divide up relative to mature global market demand for these "products" (I hesitate to describe such potential life changing miracle treatments in such banal commercial terms - but this is financial analysis and so that is the lense for investors).

Rather I think we are very early in this space. Still nascent, but about to bloom.

Long hold a position in the lot as an investor - and thereby spread your risk over multiple shots on goal for approval.

Traders can assess for themselves sentiment, momentum and risk/ reward profiles for each - they have The Time/ Attention space to do so.

@RuddyRolls CMPS 4-5x at FDA approval sounds about right. Until HELP proves itself in phase 3 results I expect it will continue to be given a low valuation due to the low enrollment in its Phase 2. I think DFTX is going to stall at its present share price for quite a while since it is probably pricing in the GAD results coming up.

StockTwits Web

 CMPS 4-5x at FDA approval sounds about right. Until HELP proves itself in phase 3 results I expect it will continue to be given a low valuation due to the low enrollment in its Phase 2. I think DFTX is going to stall at its present share price for quite a while since it is probably pricing in the GAD results coming up.

@BankOnTheFuture yes HELP has more beta till the higher powered phase 3 data drops.

Nonetheless its phase 2 remission rates were fairly astonishing. (Even for me a True Belieber in the bovine-dung-shroom as sacrament).

 yes HELP has more beta till the higher powered phase 3 data drops.

Nonetheless its phase 2 remission rates were fairly astonishing. (Even for me a True Belieber in the bovine-dung-shroom as sacrament).

@RuddyRolls im not sure if this is considered early any more. Maybe for $HELP or $DFTX but $CMPS is going to be in the commercialization phase in 6 months. Time to load up on the obvious first mover.

Chankster09

 im not sure if this is considered early any more. Maybe for 

 is going to be in the commercialization phase in 6 months. Time to load up on the obvious first mover.

@Millionaire11 anything that has a clean and clear pathway to mature to 20-100x is still early.

I&#39;m thinking about this from a 2050 perspective.

;)

 anything that has a clean and clear pathway to mature to 20-100x is still early.

I'm thinking about this from a 2050 perspective.

;)

@RuddyRolls I appreciate that perspective but the reality is big pharma will gobble most of these companies up in the next 5 years.

Kai Haskins

$HELP yes, certainly on acquisition target radar.

https://www.fiercebiotech.com/biotech/rising-tide-scenario-why-other-big-pharmas-could-follow-lilly-psychedelics

 I appreciate that perspective but the reality is big pharma will gobble most of these companies up in the next 5 years.

@Millionaire11 let&#39;s see.

Might be a new big farmer&#39;s kid on the block yet. Or two.

Some of those involved are quite idealistic - and visionary. And have long game legs on them personally.

;)

 let's see.

Might be a new big farmer's kid on the block yet. Or two.

Some of those involved are quite idealistic - and visionary. And have long game legs on them personally.

;)

@RuddyRolls @Millionaire11 Price is aligned with how closely the companies are to FDA approval, and what their drugs treat. DFTX is the only drug aiming to treat general anxiety. Drug resistant depression is a much smaller market even though CMPS is closer to FDA approval.

Jarrett Northup

@laidbacklu $DFTX 

$CMPS COMP360 (TRD) will be deployed off-label no doubt - as only approved in first few years.

$HELP has a candidate for Generalized Anxiety Disorder (GAD): HLP004. 

&quot;A proprietary deuterated formulation of $N,N$-dimethyltryptamine (DMT) administered via intramuscular injection, paired with psychotherapy.

Clinical Findings: Topline Phase 2 data revealed clinically meaningful reductions in anxiety, with durable remission rates extending up to six months following treatment, and no drug-related serious adverse events reported. 

Patent Protection: Helus Pharma holds robust intellectual property and patent coverage for this deuterated DMT program.&quot;

https://finance.yahoo.com/news/cybin-help-down-27-3-131141505.html

 Price is aligned with how closely the companies are to FDA approval, and what their drugs treat. DFTX is the only drug aiming to treat general anxiety. Drug resistant depression is a much smaller market even though CMPS is closer to FDA approval.

@RuddyRolls There are ~12 million remaining warrants that will issue for CMPS before February. These will add around $110 million to the bank and take final share count to ~147 million with expanded runway to 2029. CMPS will be at approval and launch timing with half a billion in cash. 
 
HELP has roughly $160–170M cash, roughly 62M shares after its latest offering, a $100M ATM which must be used by October, and a $1.7 billion shelf it would have to use in the next year. Its second pivotal trial is still enrolling, its NDA is targeted for 2028, and commercial launch is more likely in late 2029–early 2030. At its current burn, it needs another $140–240M just to reach NDA submission, $250–400M more to reach launch, and potentially $400–600M to launch with one year of runway. 
 
That funding will add up to 100 million more shares. The valuation gap between cmps and HELP reflects clinical risk, regulatory timing, 3 years of earlier revenue, balance-sheet strength, and far lower dilution risk.

Cynthia

Murphy Invests

 There are ~12 million remaining warrants that will issue for CMPS before February. These will add around $110 million to the bank and take final share count to ~147 million with expanded runway to 2029. CMPS will be at approval and launch timing with half a billion in cash. 
 
HELP has roughly $160–170M cash, roughly 62M shares after its latest offering, a $100M ATM which must be used by October, and a $1.7 billion shelf it would have to use in the next year. Its second pivotal trial is still enrolling, its NDA is targeted for 2028, and commercial launch is more likely in late 2029–early 2030. At its current burn, it needs another $140–240M just to reach NDA submission, $250–400M more to reach launch, and potentially $400–600M to launch with one year of runway. 
 
That funding will add up to 100 million more shares. The valuation gap between cmps and HELP reflects clinical risk, regulatory timing, 3 years of earlier revenue, balance-sheet strength, and far lower dilution risk.